SCI时时刷

search
Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Introduction Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo+Bev) and...
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular car...
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
Background: Checkpoint inhibitors act on exhausted CD8+ T cells and restore their effector function in chronic infections ...
Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice
Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice
Introduction: Previous research has demonstrated that an isocaloric diet rich in trans fatty acid (TFA), saturated fatty a...
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningf...
Hepatitis B virus treatment and hepatocellular carcinoma - controversies and approaches to consensus
Hepatitis B virus treatment and hepatocellular carcinoma - controversies and approaches to consensus
Background: Long-term therapy with nucleos(t)ide analogues (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate...
First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Introduction: Sorafenib was historically the standard of care for advanced hepatocellular carcinoma (aHCC) until it was su...
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly ...
Sulfatase-2 from cancer associated fibroblasts – an environmental target for hepatocellular carcinoma?
Sulfatase-2 from cancer associated fibroblasts – an environmental target for hepatocellular carcinoma?
Introduction: Heparin sulfate proteoglycans in the liver tumour microenvironment (TME) are key regulators of cell signalin...
Response to Kong-Ying Lin, Shi-Chuan Tang, Cheung-Wu Zhang, Yong-Yi Zeng, Tian Yang
Response to Kong-Ying Lin, Shi-Chuan Tang, Cheung-Wu Zhang, Yong-Yi Zeng, Tian Yang
We thank Lin KY et al for their comments on our manuscript entitled “Use of antibiotics during immune checkpoint inhibitor...
REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma:  RELEVANT study
REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study
Introduction: In the REFLECT trial, lenvatinib was found to be non-inferior compared to sorafenib in terms of Overall Surv...